Physician profile
Ty O Hanson
NPI 1396804597
$982,075.43
in general payments reported to CMS, 2019-2025
26 companies · $179K in 2025
The $179K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $50K · 2021: $100K · 2022: $129K · 2023: $174K · 2024: $269K · 2025: $179K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $530K · Travel and Lodging: $73K · Food and Beverage: $16K · Consulting Fee: $4,380 · Education: $527 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $529,510.57 |
| Travel and Lodging | $72,523.77 |
| Food and Beverage | $15,518.27 |
| Consulting Fee | $4,380.00 |
| Education | $527.33 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $300,617.07 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Abbvie INC. | $144,867.54 | 2019-2025 | |
| Janssen Biotech, INC. | $120,005.64 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $97,243.24 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $51,458.94 | 2019-2025 | Otezla, Enbrel, Amjevita |
| Ucb, INC. | $49,639.57 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $44,461.52 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $44,297.98 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $35,548.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $33,095.51 | 2019-2025 | |
| Celgene Corporation | $32,557.20 | 2019 | |
| Janssen Scientific Affairs, LLC | $22,556.17 | 2021-2025 | Tremfya |
| Helsinn Therapeutics (U.S.), INC. | $4,465.03 | 2019 | |
| Sun Pharmaceutical Industries INC. | $348.41 | 2019-2025 | Ilumya |
| Pfizer INC. | $190.41 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $130.65 | 2020-2025 | Grafix, Grafix Pl, Oasis |
| Incyte Corporation | $117.28 | 2021-2025 | Opzelura |
| Johnson & Johnson Health Care Systems INC. | $100.29 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $85.86 | 2023-2025 | Zoryve |
| Strata Skin Sciences, INC. | $71.17 | 2022-2025 | Xtrac |
| Dermavant Sciences, INC. | $67.17 | 2022-2023 | Vtama |
| Kyowa Kirin, INC. | $60.75 | 2024-2025 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.95 | 2020 | |
| Merck Sharp & Dohme LLC | $22.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.81 | 2025 | Koselugo |
| Organon LLC | $5.84 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ty Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.